Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03603977
Recruiting Observational

Simplified Treatment of Anti-retrovirus in China (C-STAR)

NCT03603977 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou 8th People's Hospital
Phase
Observational
Started
2017-11-01
Last updated
2022-09-14

Condition(s) studied

HIV/AIDS

Investigational drug(s) / intervention(s)

Lpv/r+3TCAll LPV/r trials (3) →All Gammora trials (5) →

Lpv/r+3TC: It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.

Study summary

To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. HIV-1 infection confirmed 2. Agree to use simplified therapy regimen. 3. Agree to detect CD4 count at least once per half a year Exclusion Criteria: 1. Have participated in HIV vaccine clinical trial or other drug trials in the past three months. 2. Patients who could not complete the scheduled follow-up (such as weakness and poor compliance). 3. Patients who have the history of resistance or allergy to LPV/r or 3TC.

Primary outcome measure(s)

  • The rate of virus inhibition — 36 Months
    the ratio of HIV RNA\< 50 copies/mL at 12, 24 or 36 months after treatment.

Trial sites (1)

FacilityCityRegionStatus
Guangzhou 8th People's Hospital Guangzhou Guangdong Recruiting

More Guangzhou 8th People's Hospital trials in China

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads Recruiting
Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock Recruiting
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function Recruiting
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia Recruiting
Observational Study on Patients With HIV/AIDS(OSPWH) Recruiting

Other trials for the same condition

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function Recruiting
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease Recruiting
Dolutegravir Plus Lamivudine Simplified Therapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03603977 on ClinicalTrials.gov ↗ ← All trials in China